Arbutus Biopharma Corporation Stock News
$4.20
1.64%
yesterday
Nasdaq,
Nov 20, 10:00 pm CET
Arbutus Biopharma Corporation Stock News
Neutral
GlobeNewsWire
●
8 days ago
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional analysis of imdusiran (AB-729) clinical data shows: - 46% of Phase 2a patients met criteria to discontinue all treatment - 94% of long-term f...
Neutral
GlobeNewsWire
●
about one month ago
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused o...
Positive
The Motley Fool
●
4 months ago
Arbutus (ABUS) Q2 Revenue Surges 529%
Neutral
GlobeNewsWire
●
4 months ago
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran
Neutral
GlobeNewsWire
●
5 months ago
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
